Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy
Principal Investigator
Ronald Chen, MD MPH
Status
Closed to Accrual
Date Opened To Accrual
March 27 2019
Disease Site
Cancer Care Delivery Research [CD]
Other
Phase
II
Developmental Therapeutics
No
Primary Objective
To determine if the experimental arm (increased doses of SCP) has more patients who saw a primary care provider and had blood glucose and cholesterol checked in Year 2 (13-24 months) after finishing RT as compared to the control arm.
Patient Population
The participant must have a diagnosis of prostate adenocarcinoma that will be treated with RT plus ADT with curative intent. Both definitive RT (intact prostate) and post-prostatectomy RT patients are eligible.
Target Accrual
544
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.